Opinion|Videos|January 13, 2025
Discussing Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with cGVHD
Author(s)Sergio A. Giralt, MD
Sergio A. Giralt, MD, discusses how he selects patients with chronic graft-vs-host disease (cGVHD) for treatment with ruxolitinib, often in combination with corticosteroids, and reviews the study design and methods of recent research on ruxolitinib in cGVHD management, highlighting key efficacy and safety results and how these findings align with his clinical practice.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Which patients with chronic graft-vs-host disease (cGVHD) do you treat with ruxolitinib in your clinical practice?
- Do you use corticosteroids concurrently with ruxolitinib?
- What were this abstract’s study design and methods, and why was it important to investigate for cGVHD management?
- What were the key efficacy and safety results seen in this abstract?
- Do these results align with what you see in your clinical practice?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
AI-Supported Mammography Caught More Cancers During Screening
2
Combination Therapy, Biologics, and Surgery Redefine HS Care in 2026
3
AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule
4
The Strategic Necessity of Pharma-MedTech Convergence in an Era of Precision Medicine
5
